JAMA Surgery:自体脂肪用于乳房重建满意度更高

2017-06-29 贾朝娟 环球医学资讯

根据《JAMA Surgery》发表的一项研究显示,使用脂肪移植术作为乳房切除术后乳房重建的工具,或可改善乳房满意度、心理健康和性幸福感。

根据《JAMA Surgery》发表的一项研究显示,使用脂肪移植术作为乳房切除术后乳房重建的工具,或可改善乳房满意度、心理健康和性幸福感。

脂肪移植作为乳房重建的辅助手段,包括通过吸脂从腹部或大腿获取脂肪细胞,去除多余的物质来分离脂肪细胞,然后将其少量注射到重建的缺损区域。脂肪移植已被证明是轮廓不规则和体积缺陷的乳房再造的一个有用的辅助治疗,但美国食品和药物管理局正在考虑法规可能会严重限制了整形外科医生继续其用于这一目的的能力。密歇根大学健康系的Jeffrey H. Kozlow和他的同事进行了一项研究,纳入了2048例乳房切除术后进行乳房重建的女性。

在这些妇女中,165(8%)例在手术后1至2年间接受了脂肪移植。术后一年,随后不接受脂肪移植的患者与接受脂肪移植的患者相比,乳房满意度、心理健康和性幸福感显着降低。手术后,术后2年测量脂肪移植组报告相似的乳房满意度。

作者写到,通过提供多中心、前瞻性的数据,证实自体脂肪移植作为乳房重建一种有用的辅助手段的好处,我们希望这项研究将有助于持续与付款人和监管机构对这一手术的安全性和有效性进行讨论。这一研究结果支持脂肪移植是乳房重建的一个重要工具,这一选择应该作为重建外科医生和他们所服务患者的一个可用选择。

该研究的局限性为与任何非随机对照研究设计相似,在结果分析中可能有未校正的未知的混杂因素。

原始出处:
Bennett, K. G., et al.Association of Fat Grafting With Patient-Reported Outcomes in Postmastectomy Breast Reconstruction.JAMA Surg. 2017 Jun 28. doi: 10.1001/jamasurg.2017.1716. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2021580, encodeId=8a002021580b7, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Oct 29 19:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877700, encodeId=fb1f18e770017, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Sun Oct 29 23:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478650, encodeId=d3ce14e865094, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Jul 01 09:09:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544052, encodeId=064f1544052cb, content=<a href='/topic/show?id=610d266582b' target=_blank style='color:#2F92EE;'>#体脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26658, encryptionId=610d266582b, topicName=体脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e74a13632472, createdName=ms4964546379600229, createdTime=Sat Jul 01 09:09:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2021580, encodeId=8a002021580b7, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Oct 29 19:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877700, encodeId=fb1f18e770017, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Sun Oct 29 23:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478650, encodeId=d3ce14e865094, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Jul 01 09:09:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544052, encodeId=064f1544052cb, content=<a href='/topic/show?id=610d266582b' target=_blank style='color:#2F92EE;'>#体脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26658, encryptionId=610d266582b, topicName=体脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e74a13632472, createdName=ms4964546379600229, createdTime=Sat Jul 01 09:09:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
    2017-10-29 chg121
  3. [GetPortalCommentsPageByObjectIdResponse(id=2021580, encodeId=8a002021580b7, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Oct 29 19:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877700, encodeId=fb1f18e770017, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Sun Oct 29 23:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478650, encodeId=d3ce14e865094, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Jul 01 09:09:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544052, encodeId=064f1544052cb, content=<a href='/topic/show?id=610d266582b' target=_blank style='color:#2F92EE;'>#体脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26658, encryptionId=610d266582b, topicName=体脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e74a13632472, createdName=ms4964546379600229, createdTime=Sat Jul 01 09:09:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2021580, encodeId=8a002021580b7, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Oct 29 19:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877700, encodeId=fb1f18e770017, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Sun Oct 29 23:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478650, encodeId=d3ce14e865094, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Sat Jul 01 09:09:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544052, encodeId=064f1544052cb, content=<a href='/topic/show?id=610d266582b' target=_blank style='color:#2F92EE;'>#体脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26658, encryptionId=610d266582b, topicName=体脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e74a13632472, createdName=ms4964546379600229, createdTime=Sat Jul 01 09:09:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]